ライフサイエンスコーパス: mitral regurgitation

1 tion at 1 year (6.0% of patients with severe mitral regurgitation).

2 art Association class, large QRS, and severe mitral regurgitation).

3 ely used in high surgical risk patients with mitral regurgitation.

4 mitral valve repair in patients with primary mitral regurgitation.

5 TR only occurred in those with no/trace/mild mitral regurgitation.

6 us in future repair algorithms for secondary mitral regurgitation.

7 opment of new repair techniques for ischemic mitral regurgitation.

8 l spectrum is associated with higher risk of mitral regurgitation.

9 , which was similar for FMR and degenerative mitral regurgitation.

10 ntricular size, that governs the severity of mitral regurgitation.

11 ce and severity of LV dysfunction in organic mitral regurgitation.

12 alve disease, particularly in the setting of mitral regurgitation.

13 e as predictors of prognosis in asymptomatic mitral regurgitation.

14 stic value in the management of asymptomatic mitral regurgitation.

15 rategy to improve the lives of patients with mitral regurgitation.

16 rformed in most elderly patients with severe mitral regurgitation.

17 n alternative to surgery for treating severe mitral regurgitation.

18 ejection fraction (EF) impairment in organic mitral regurgitation.

19 his large population of patients with severe mitral regurgitation.

20 pair and replacement in patients with native mitral regurgitation.

21 es of percutaneous repair versus surgery for mitral regurgitation.

22 nal (45%), degenerative (48%), or mixed (6%) mitral regurgitation.

23 s after mitral valve repair for degenerative mitral regurgitation.

24 ischemic mitral regurgitation and myxomatous mitral regurgitation.

25 egurgitation and 11 patients with myxomatous mitral regurgitation.

26 .38; 95% confidence interval, 1.27-4.45) for mitral regurgitation.

27 e distinction between organic and functional mitral regurgitation.

28 able to less severe and subclinical cases of mitral regurgitation.

29 ol may be of importance in the prevention of mitral regurgitation.

30 h an increased risk of primary and secondary mitral regurgitation.

31 ter mitral valve repair for the treatment of mitral regurgitation.

32 f the indication for surgery in degenerative mitral regurgitation.

33 reated in Yorkshire swine by inducing severe mitral regurgitation.

34 antly more recurrences of moderate or severe mitral regurgitation.

35 ef in such patients via reduction of SAM and mitral regurgitation.

36 ts with moderate-to-severe or severe organic mitral regurgitation.

37 of percutaneous interventions for functional mitral regurgitation.

38 strain intensity was higher in patients with mitral regurgitation (0.15+/-0.03) than in normals (0.11

39 re were 3950 patients with any VHD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation,

40 dence interval, 2.03-6.21) for aortic and/or mitral regurgitation, 19.8% versus 4.7% (odds ratio, 5.2

41 IPMD, mitral valve geometry, and severity of mitral regurgitation, 67 patients with ischemic heart di

42 ed in patients with moderate/severe ischemic mitral regurgitation (9.6 +/- 2.8 mm), but preserved in

43 Both ischemic mitral regurgitation (9.98 +/- 155 cm(2)) and myxomatous

44 Acute improvement in mitral regurgitation after TAVR is predominantly related

45 absence of SAM and significant reduction in mitral regurgitation, although high systolic LVOT veloci

46 1 normal subjects, 11 patients with ischemic mitral regurgitation and 11 patients with myxomatous mit

47 p period, 28,655 (0.52%) were diagnosed with mitral regurgitation and a further 1,262 (0.02%) were di

48 in significantly reduced rates of recurrent mitral regurgitation and adverse cardiac events over tim

49 le to provide insights into the mechanism of mitral regurgitation and also to help discern the conseq

50 nular incisions resulted in mild to moderate mitral regurgitation and an increased vena contracta are

51 superior repair with decreased recurrence of mitral regurgitation and enhanced reversal of left ventr

52 ustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptom

53 It can manifest as mitral regurgitation and is the leading indication for m

54 al annular dynamics are impaired in ischemic mitral regurgitation and myxomatous mitral regurgitation

55 In both ischemic mitral regurgitation and myxomatous mitral regurgitation

56 In asymptomatic patients with >/=3+ mitral regurgitation and preserved left ventricular (LV)

57 1+/-12 years and 69% men) with >/=3+ primary mitral regurgitation and preserved left ventricular ejec

58 ymptomatic patients with significant primary mitral regurgitation and preserved left ventricular ejec

59 alvulopathy (>/= mild aortic or >/= moderate mitral regurgitation) and changes in regurgitant grade a

60 cardiac magnetic resonance and no or trivial mitral regurgitation, and 16 (6 female patients; median

61 et mobility, decreased severity of recurrent mitral regurgitation, and improved reverse remodeling wi

62 lmonale, left ventricular ejection fraction, mitral regurgitation, and inferior vena cava variability

63 controls and patients with aortic stenosis, mitral regurgitation, and left ventricular assist device

64 apy, implantable cardioverter defibrillator, mitral regurgitation, and mitral valve procedures; an in

65 New York Heart Association functional class, mitral regurgitation, and N-terminal pro-B-type natriure

66 ree survival was predicted by age, degree of mitral regurgitation, and postprocedural hemodynamic dat

67 k surgery, symptomatic severe AS, coexisting mitral regurgitation, and preexisting coronary disease w

68 etic resonance (CMR) can accurately quantify mitral regurgitation, and we examined whether this was a

69 ischemic mitral regurgitation and myxomatous mitral regurgitation, annular dynamics and anatomy are a

70 In myxomatous mitral regurgitation, annular dynamics were also markedl

71 gitation (9.98 +/- 155 cm(2)) and myxomatous mitral regurgitation annuli (13.29 +/- 3.05 cm(2)) were

72 In general, ischemic mitral regurgitation annuli were less dynamic than contr

73 ography evidence of at least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve su

74 ng severe or mild/moderate LV dysfunction in mitral regurgitation are doubted and poorly followed in

75 linical outcomes after surgical treatment of mitral regurgitation are worse if intervention occurs af

76 e also treated with the MitraClip system for mitral regurgitation as a combined procedure.

77 recommended in patients with severe primary mitral regurgitation as soon as ejection fraction (EF) <

78 owed a persistent reduction in the degree of mitral regurgitation at 1 year (6.0% of patients with se

79 The rate of moderate or severe recurrence of mitral regurgitation at 12 months was higher in the repa

80 f death was only found in those with minimal mitral regurgitation at baseline.

81 06; P = .02), presence of moderate or severe mitral regurgitation at discharge (1.65; 95% CI, 1.21-2.

82 Forty-one patients with severe mitral regurgitation being considered for transcatheter

83 s) undergoing primary repair of degenerative mitral regurgitation between 2003 and 2011, 419 (65%) un

84 h a reduced prevalence of moderate or severe mitral regurgitation but an increased number of untoward

85 repair provided a more durable correction of mitral regurgitation but did not significantly improve s

86 h a reduced prevalence of moderate or severe mitral regurgitation, but patients had more adverse even

87 cement provided a more durable correction of mitral regurgitation, but there was no significant betwe

88 ventricular size, shape, and mass and reduce mitral regurgitation by reverse remodeling of the failin

89 a common condition that is a risk factor for mitral regurgitation, congestive heart failure, arrhythm

90 c, severe functional, degenerative, or mixed mitral regurgitation deemed at high risk or inoperable.

91 DMD does not incur more severe mitral regurgitation, despite larger prolapse and valve

92 in follow-up intervals for TTE assessment of mitral regurgitation, despite risk-adjustment for patien

93 ndependent of age, end-systolic volume, sex, mitral regurgitation, diabetes mellitus, dyslipidemia, c

94 with symptomatic functional or degenerative mitral regurgitation (DMR) at high surgical risk.

95 Clip implantation in noncentral degenerative mitral regurgitation (dMR) compared with central dMR.

96 ns the gold standard for severe degenerative mitral regurgitation (DMR).

97 tween EF and mortality in 1875 patients with mitral regurgitation due to flail leaflets in sinus rhyt

98 Proper identification of these severe mitral regurgitation due to these disease valves will he

99 ; 64% male) with isolated moderate to severe mitral regurgitation (effective regurgitant orifice area

100 time, ejection time, total isovolumic time, mitral regurgitation, ejection fraction, and blood press

101 After mitral valve repair for degenerative mitral regurgitation, elevated mitral gradients is not u

102 impairs their systolic closure, resulting in mitral regurgitation, even in small ventricles.

103 Only patients with functional mitral regurgitation experienced significant reduction o

104 The prevalent pathogenesis was functional mitral regurgitation (FMR) (n = 452 [72.0%]).

105 and medical treatment options for functional mitral regurgitation (FMR) are limited and additional in

106 y mechanism capable of preventing functional mitral regurgitation (FMR) in dilated ventricles.

107 c left ventricular (LV) function, functional mitral regurgitation (FMR), and pulmonary hypertension (

108 ortic regurgitation (AR) prevents functional mitral regurgitation (FMR).

109 quantified as risk factors for recurrence of mitral regurgitation following reduction annuloplasty.

110 py has emerged as an option for treatment of mitral regurgitation for selected, predominantly high-ri

111 tery disease and moderate or severe ischemic mitral regurgitation from 1990 to 2009, categorized by m

112 7 [1.43-2.20]), male sex (1.69 [1.32-2.16]), mitral regurgitation grade >/=III (1.61 [1.15-2.25]), hi

113 - 11 mm Hg to 20 +/- 8 mm Hg; p = 0.06), and mitral regurgitation grade (3.0 +/- 0 vs. 0.8 +/- 0.4; p

114 , defined as valve area >/=1.5 cm(2) without mitral regurgitation >2/4, were obtained in 912 patients

115 ts with echocardiographic moderate or severe mitral regurgitation had baseline CMR scans and were fol

116 Patients with organic mitral regurgitation have higher strain than normals.

117 SBP was associated with a 26% higher risk of mitral regurgitation (hazard ratio [HR] 1.26; CI 1.23, 1

118 athy of unknown etiology that predisposes to mitral regurgitation, heart failure and sudden death.

119 valve prolapse, associated with symptomatic mitral regurgitation, heart failure, and death.

120 maller LA volumes, better function, and less mitral regurgitation, HFpEF patients had more atrial fib

121 dence interval [CI] 2.77-11.33), presence of mitral regurgitation (HR 8.13, 95% CI 4.09-12.16), lower

122 (HR, 10.2; 95% CI, 3.2-32.2; P < .001), and mitral regurgitation (HR, 4.78; 95% CI, 1.4-16.0; P = .0

123 Of all patients, mitral regurgitation improved in 54%, remained the same

124 In ischemic mitral regurgitation (IMR), ring annuloplasty is associa

125 Mitral regurgitation in people without prior cardiac dis

126 , low stroke volume, and greater severity of mitral regurgitation in SAVR patients.

127 (mean age, 61 years +/- 19; nine male) with mitral regurgitation in the 24 hours before mitral valve

128 Despite the anatomical complexity of mitral regurgitation in the patients in this compassiona

129 eatment of asymptomatic patients with severe mitral regurgitation in valve reference centres, in whic

130 clinical risk factors, severity of ischemic mitral regurgitation, incomplete revascularization, and

131 cal risk factors, end-systolic volume index, mitral regurgitation, incomplete revascularization, and

132 At 1 month after mitral regurgitation induction, pigs developed HF as evi

133 One month after mitral regurgitation induction, pigs were randomized to

134 s; median EF, 66% [60%-71%]) enrolled in the Mitral Regurgitation International Database (MIDA) regis

135 MIDA (Mitral Regurgitation International Database) is a multic

136 Severe mitral regurgitation is a common and complex disease tha

137 PURPOSE OF REVIEW: Mitral regurgitation is a growing public concern affecti

138 Ischemic mitral regurgitation is associated with a substantial ri

139 Severe mitral regurgitation is associated with impaired prognos

140 Ischemic mitral regurgitation is associated with increased mortal

141 ing surgical timing for asymptomatic chronic mitral regurgitation is controversial.

142 Surgery for severe mitral regurgitation is indicated if symptoms or left ve

143 ographic (TTE) surveillance of patients with mitral regurgitation is indicated to avoid adverse ventr

144 Significant mitral regurgitation is present in more than 10% of this

145 e primary imaging modality for assessment of mitral regurgitation, it may be inadequate or suboptimal

146 placement, thickness, coaptation height, and mitral regurgitation jet height (all P<0.05).

147 ons onto the annulus, coaptation height, and mitral regurgitation jet height in 261 Framingham Offspr

148 iteria, first tested in a preliminary phase, mitral regurgitation jet length>/=2 cm or any aortic reg

149 s with MVP (17%) had moderate or more severe mitral regurgitation (jet height >/=5 mm) and 5 others (

150 Significant myxomatous mitral regurgitation leads to progressive left ventricul

151 diate results (valve area >/= 1.5 cm(2) with mitral regurgitation </= 2/4) were obtained in 251 patie

152 Clinical and echocardiographic data (mitral regurgitation, LV ejection fraction, LV dimension

153 In patients with secondary mitral regurgitation, mainly a disease of the left ventr

154 age and postprocedural variables, including mitral regurgitation, mean gradient, and pulmonary press

155 on the long-term association between SBP and mitral regurgitation (mediator-adjusted HR 1.22; CI 1.20

156 itral valve annuloplasty (RMA) for secondary mitral regurgitation might cause functional mitral steno

157 In elderly patients with mitral regurgitation, mitral valve repair is associated

158 ViR group had more frequent post-procedural mitral regurgitation moderate or higher (19.4% vs. 6.8%;

159 lar ejection fraction, worse post-procedural mitral regurgitation, moderate or severe lung disease, d

160 lve (MV) disease is a common cause of severe mitral regurgitation (MR) and accounts for the majority

161 The timing of surgery in patients with mitral regurgitation (MR) and aortic regurgitation (AR)

162 this study was to characterize patients with mitral regurgitation (MR) and atrial fibrillation (AF) t

163 The relationship between treatment of mitral regurgitation (MR) and renal function is not well

164 uretic peptide (BNP) may predict outcomes of mitral regurgitation (MR) are plagued by small size, inc

165 ra, California) in patients with significant mitral regurgitation (MR) at high risk of surgical morta

166 l aggregation has been described for primary mitral regurgitation (MR) caused by mitral valve prolaps

167 alternative for patients with severe primary mitral regurgitation (MR) considered at high or prohibit

168 g its determinants or its effect on ischemic mitral regurgitation (MR) development.

169 Patients with severe mitral regurgitation (MR) due to isolated posterior prol

170 The development of secondary mitral regurgitation (MR) due to left ventricular dysfun

171 The risk for and consequences of recurrent mitral regurgitation (MR) following degenerative mitral

172 Of these 166 patients, 9% had mitral regurgitation (MR) grade >2, and 10% had MR grade

173 stratification of patients with significant mitral regurgitation (MR) has not been studied.

174 Surgical approaches to correct mitral regurgitation (MR) have evolved over 50 years and

175 nal morphology of mitral valve and degree of mitral regurgitation (MR) in mitral valve prolapse.

176 ications and suitable operative strategy for mitral regurgitation (MR) in patients with HOCM.

177 This study aimed to evaluate treatment of mitral regurgitation (MR) in patients with severe DMR at

178 bbott Vascular, Santa Clara, California) for mitral regurgitation (MR) in the United States.

179 t subclavian artery, misdiagnosed as primary mitral regurgitation (MR) in transthoracic echocardiogra

180 Mitral regurgitation (MR) is a complex valve lesion that

181 Ischemic mitral regurgitation (MR) is a frequent complication of

182 Primary mitral regurgitation (MR) is a growing health problem du

183 Symptomatic mitral regurgitation (MR) is associated with high morbid

184 Secondary mitral regurgitation (MR) is associated with poor outcom

185 Mitral regurgitation (MR) is associated with reduced sur

186 Undersized ring annuloplasty for ischemic mitral regurgitation (MR) is associated with variable re

187 Mitral regurgitation (MR) is associated with worse survi

188 iseases of the mitral valve (MV) that causes mitral regurgitation (MR) is broad, and there is limited

189 Significant mitral regurgitation (MR) is frequent in patients with s

190 Mitral regurgitation (MR) is one of the most prevalent v

191 ere aortic stenosis and concomitant relevant mitral regurgitation (MR) is present in 30% to 55% of th

192 Severe primary (degenerative) mitral regurgitation (MR) is repaired with durable resul

193 Mitral regurgitation (MR) is the most common valve disea

194 Mitral regurgitation (MR) is the most common valvular he

195 ng (CABG) in patients with moderate ischemic mitral regurgitation (MR) is uncertain.

196 Mitral regurgitation (MR) of mitral valve prolapse predo

197 The effect of preoperative mitral regurgitation (MR) on clinical outcomes of patien

198 of this study was to evaluate the impact of mitral regurgitation (MR) on outcomes after transcathete

199 e is known of the prognostic significance of mitral regurgitation (MR) on transcatheter aortic valve

200 Percutaneous repair of mitral regurgitation (MR) permits examination of the eff

201 Mitral regurgitation (MR) produces sympathetic nervous s

202 Mechanisms of mitral regurgitation (MR) reduction with cardiac resynch

203 nts with chronic severe primary degenerative mitral regurgitation (MR) remains controversial, and fur

204 improves survival in patients with ischemic mitral regurgitation (MR) remains unknown.

205 All patients treated had functional mitral regurgitation (MR) secondary to ischemic cardiomy

206 tic patients make the accurate assessment of mitral regurgitation (MR) severity even more important.

207 Accurate assessment of mitral regurgitation (MR) severity is important for clin

208 MitraClip has been shown to reduce mitral regurgitation (MR) severity safely but to a lesse

209 stroke volume technique (patients) to assess mitral regurgitation (MR) severity using real-time volum

210 onsecutive patients with severe degenerative mitral regurgitation (MR) were treated with a mitral val

211 though surgery is indicated in patients with mitral regurgitation (MR) when left ventricular (LV) end

212 lve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous devi

213 ering by displaced papillary muscles induces mitral regurgitation (MR), which doubles mortality.

214 nt of prohibitive-risk patients with primary mitral regurgitation (MR).

215 ction in volume overload induced by isolated mitral regurgitation (MR).

216 rformed without annuloplasty in degenerative mitral regurgitation (MR).

217 ion of chronic aortic regurgitation (AR) and mitral regurgitation (MR).

218 herapy for patients with symptomatic, severe mitral regurgitation (MR).

219 atients with chronic, isolated, degenerative mitral regurgitation (MR).

220 nd surgery for patients with severe ischemic mitral regurgitation (MR).

221 Only patients with functional mitral regurgitation (n = 71) experienced an acute reduc

222 on fraction, 60% [45%-67%]; all </= moderate mitral regurgitation; n=6 with previous cardiac arrest a

223 sms and treatments of nonischemic functional mitral regurgitation (NIMR) are not fully established, i

224 l patients, resulting in procedural residual mitral regurgitation of grade 2+ or less in 22 (96%) pat

225 d for the quantitative assessment of organic mitral regurgitation (OMR).

226 The rate of recurrence of moderate or severe mitral regurgitation over 2 years was higher in the repa

227 MVP progresses to significant mitral regurgitation over a period of 3 to 16 years in o

228 (95.4%) and similar in FMR and degenerative mitral regurgitation (p = 0.662).

229 Mean age was 77+/-14 years; 71% male (n=29); mitral regurgitation pathogenesis was functional in 54%

230 2000 and December 2011 (excluding functional mitral regurgitation, prior valvular surgery, hypertroph

231 Mitral regurgitation recurred more frequently in the rep

232 2014, with hospital mortality of 2% and with mitral regurgitation reduced to grade </=2 in 87% of pat

233 greater tubular ascending aorta, presence of mitral regurgitation, reduced left ventricular ejection

234 ographic core analysis after 6 months showed mitral regurgitation reduction in 50% of treated patient

235 +/-12 years, 138 males) with chronic organic mitral regurgitation referred to surgery underwent an ec

236 In patients with organic mitral regurgitation referred to surgery, RV function im

237 ular and atrial dimensions (all P>0.55), and mitral regurgitation regurgitant orifice (P=0.62).

238 The optimal treatment for ischemic mitral regurgitation remains actively debated.

239 % versus 69%; P=0.003), and in patients with mitral regurgitation, reproducibility was improved with

240 months for severe, moderate, mild, and trace mitral regurgitation, respectively, with 20% of provider

241 alysis, exercise ejection fraction, exercise mitral regurgitation, rest and exercise tricuspid annula

242 spid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or su

243 There was an interaction between TR and mitral regurgitation severity (P=0.04); the increased ha

244 le quantitation of cardiac remodeling and of mitral regurgitation severity and of annular and valvula

245 que is complex, and common methods to define mitral regurgitation severity based on 2-dimensional (2D

246 ggravating role of tissue paucity of FED) on mitral regurgitation severity.

247 ificant difference in these results based on mitral regurgitation severity.

248 has emerged as a robust modality to quantify mitral regurgitation severity.

249 h rate of technical success and reduction of mitral regurgitation severity.

250 Elderly patients with severe mitral regurgitation should be referred for operation be

251 t ventricular (LV) dysfunction and secondary mitral regurgitation (SMR) are still controversial.

252 Secondary mitral regurgitation (SMR) is generally reduced after is

253 nd then according to atrial fibrillation and mitral regurgitation status.

254 with outcomes, mixed data on SMR and primary mitral regurgitation, studies not clearly reporting the

255 In primary mitral regurgitation, surgical repair is the standard of

256 AS) was significantly lower in patients with mitral regurgitation than in healthy control subjects (P

257 mitral prolapse is the most common cause of mitral regurgitation that requires surgical treatment.

258 High Risk Patients with Severe, Symptomatic Mitral Regurgitation - The Twelve Intrepid TMVR Pilot St

259 In patients with moderate ischemic mitral regurgitation, the addition of mitral-valve repai

260 After mitral valve repair for primary mitral regurgitation, the preoperative LVEI is a new and

261 flow tract (LVOT) obstruction and associated mitral regurgitation, thereby leading to amelioration of

262 assigned 301 patients with moderate ischemic mitral regurgitation to CABG alone or CABG plus mitral-v

263 he role of EF in a large registry of organic mitral regurgitation to objectively establish thresholds

264 y assigned 251 patients with severe ischemic mitral regurgitation to undergo either mitral-valve repa

265 ay determine whether the lower prevalence of mitral regurgitation translates into a net clinical bene

266 o evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival.

267 tery disease and moderate or severe ischemic mitral regurgitation undergoing CABG alone demonstrated

268 In patients with moderate ischemic mitral regurgitation undergoing CABG, the addition of mi

269 tients with grade III+ or greater myxomatous mitral regurgitation undergoing exercise echocardiograph

270 ship between blood pressure (BP) and risk of mitral regurgitation using Cox regression models.

271 te-to-severe (grade 3+) or severe (grade 4+) mitral regurgitation using the Edwards PASCAL TMVr syste

272 to reduce systolic anterior motion (SAM) and mitral regurgitation using the transcatheter mitral clip

273 odynamic disorders can result from eccentric mitral regurgitation usually caused by chordae tendinae

274 Intervalvular mitral regurgitation was absent (47.8%) or mild (52.2%)

275 ion II score and presence of sepsis, whereas mitral regurgitation was associated with longer hospital

276 CMR quantification of mitral regurgitation was associated with the development

277 h subpapillary infarction and impaired IPMD, mitral regurgitation was evident within 1 week, compared

278 e 2-year rate of moderate or severe residual mitral regurgitation was higher in the CABG-alone group

279 Moderate or severe mitral regurgitation was less common in the combined-pro

280 PERM) by these proximate causes of secondary mitral regurgitation was only 13% (CI 6.1%, 20%), and ac

281 replacement in patients with severe ischemic mitral regurgitation, we found no significant difference

282 ve repair in patients with moderate ischemic mitral regurgitation, we found no significant difference

283 ve repair or replacement for severe ischemic mitral regurgitation, we observed no significant between

284 d that patients with </= mild postprocedural mitral regurgitation were 4-fold more likely to experien

285 ho underwent mitral valve repair for primary mitral regurgitation were studied.

286 ariable analysis, the predictors of improved mitral regurgitation were the decrease of tenting area (

287 stolic volume was increased in patients with mitral regurgitation when compared with that in healthy

288 output and mechanical efficiency and reduced mitral regurgitation, whereas reduction in chamber volum

289 our primary outcome was incident reports of mitral regurgitation, which were identified from hospita

290 ucing good outcomes in patients with primary mitral regurgitation who are at high surgical risk.

291 % men) with grade III+ or greater myxomatous mitral regurgitation who underwent exercise echocardiogr

292 egistry enrolling patients with degenerative mitral regurgitation with a flail leaflet in 6 tertiary

293 Among patients with degenerative mitral regurgitation with a flail leaflet referred to mi

294 r MV repair and replacement for degenerative mitral regurgitation with a flail leaflet.

295 SBP was continuously related to the risk of mitral regurgitation with no evidence of a nadir down to

296 of mitral valve prolapse and its associated mitral regurgitation with no or minimal requirements for

297 tus and factors influencing the reduction of mitral regurgitation with or without mitral leaflet teth

298 Surgical treatment of ischemic mitral regurgitation with reduction annuloplasty is the

299 of transapical mitral valve implantation for mitral regurgitation with the TIARA device.

300 Of 1021 patients with mitral regurgitation without the American College of Car